Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
ASTONISH investigators, Bruno François, Simon Lambden, Tom Fivez, Sebastien Gibot, Marc Derive, Jean Marie Grouin, Margarita Salcedo-Magguilli, Jérémie Lemarié, Nicolas De Schryver, Ville Jalkanen, Tarik Hicheur, Jean Jacques Garaud, Valérie Cuvier, Ricard Ferrer, Morten Bestle, Ville Pettilä, Jean Paul Mira, Camille Bouisse, Emmanuelle MercierJoris Vermassen, Vincent Huberlant, Isabelle Vinatier, Nadia Anguel, Mitchell Levy, Pierre François Laterre
Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu
19Sitaatiot
(Scopus)
Sormenjälki
Sukella tutkimusaiheisiin 'Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.